内源性大麻素系统在肌萎缩侧索硬化症中的作用研究进展
Progress in Protective Effect of the Endocannabinoids on the Amyotrophic Lateral Sclerosis
摘要: 肌萎缩侧索硬化症(ALS)是一种以上运动神经元及下运动神经元及其支配的躯干、四肢和头面部肌肉的一种慢性进行性神经变性疾病。其病因可能涉及到免疫、慢性炎症、中毒、氧化应激、病毒感染或遗传特征等。最近的研究发现内源性大麻素系统(eCBs)可能是一种保护神经元免受伤害性刺激的内源性系统，对神经变性疾病的病程有预防和治疗作用。本文阐述了eCBs对ALS的拮抗效应，对于预防和治疗ALS提供新的理论依据。
Abstract: Amyotrophic lateral sclerosis (ALS) is a chronic progressive neurodegenerative disorder pro-duced by the damage of the upper motor neurons and lower motor neurons leading to denerva-tion, atrophy and paralysis of voluntary muscles of the trunk, limbs and face. The damage of these neurons occurs by the combination of several events including immunity, chronic inflammation, excitotoxicity, oxidative stress, viral infection and genetics. Recent evidence reveals that endocannabinoids serve as preventive treatment for ALS, based on their neuroprotective and anti-inflammatory effects. Here we summarized several aspects of the protective effect of endocannabinoids on the ALS, aiming at providing a new method for the treatment of ALS.
文章引用：朱时钰, 陆永利, 杨红卫. 内源性大麻素系统在肌萎缩侧索硬化症中的作用研究进展[J]. 国际神经精神科学杂志, 2018, 7(2): 19-22. https://doi.org/10.12677/IJPN.2018.72003

参考文献

[1] Pasinelli, P. and Brown, R.H. (2006) Molecular Biology of Amyotrophic Lateral Sclerosis: Insights from Genetics. Nature Reviews. Neuroscience, 7, 710-723. [Google Scholar] [CrossRef] [PubMed]
[2] Al-Chalabi, A. and Hardiman, O. (2013) The Epidemiology of ALS: A Conspiracy of Genes, Environment and Time. Nature Reviews Neurology, 9, 617-628. [Google Scholar] [CrossRef] [PubMed]
[3] Verde, F., Del Tredici. K., Braak, H., et al. (2017) The Multisystem Degeneration Amyotrophic Lateral Sclerosis—Neuropathological Staging and Clinical Translation Ludolph A. Archives Italiennes de Biologie, 155, 118-130.
[4] Renton, A.E., Chiò, A. and Traynor, B.J. (2014) State of Play in Amyotrophic Lateral Sclerosis Genetics. Nature Neuroscience, 17, 17-23. [Google Scholar] [CrossRef] [PubMed]
[5] Pryce, G. and Baker, D. (2015) Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. Handbook of Experimental Pharmacology, 231, 213-231. [Google Scholar] [CrossRef] [PubMed]
[6] Fernández-Ruiz, J., Moro, M.A. and Martínez-Orgado, J. (2015) Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics, 12, 793-806. [Google Scholar] [CrossRef] [PubMed]
[7] Araque, A., Castillo, P.E., Manzoni, O.J., et al. (2017) Synaptic Functions of Endocannabinoid Signaling in Health and Disease. Neuropharmacology, 5, 13-24. [Google Scholar] [CrossRef] [PubMed]
[8] Xu, J. and Chen, C. (2015) Endocannabinoids in Synaptic Plasticity and Neuroprotection. Neuroscientist, 21, 152-168. [Google Scholar] [CrossRef] [PubMed]
[9] Espejo-Porras, F., Piscitelli, F., Verde, R., et al. (2015) Changes in the Endocannabinoid Signaling System in CNS Structures of TDP-43 Transgenic Mice: Relevance for a Neuroprotective Therapy in TDP-43-Related Disorders. Journal of NeuroImmune Pharmacology, 10, 233-244. [Google Scholar] [CrossRef] [PubMed]
[10] Layfield, R., Cavey, J.R. and Lowe, J. (2003) Role of Ubiquitin-Mediated Proteolysis in the Pathogenesis of Neurodegenerative Disorders. Ageing Research Reviews, 2, 343-356. [Google Scholar] [CrossRef] 
[11] Zhou, Q., Wang, Y., Zhang, J., et al. (2018) Fingerprint Analysis of Huolingshengji Formula and Its Neuroprotective Effects in SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. Scientific Reports, 8, 1668. [Google Scholar] [CrossRef] [PubMed]
[12] Bonifacino, T., Cattaneo, L., Gallia, E., et al. (2017) In-Vivo Effects of Knocking-Down Metabotropic Glutamate Receptor 5 in the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis. Neuro-pharmacology, 23, 433-445. [Google Scholar] [CrossRef] [PubMed]
[13] Navarro, G., Morales, P., Rodríguez-Cueto, C., et al. (2016) Targeting Cannabinoid CB2 Receptors in the Central Nervous System. Medicinal Chemistry Approaches with Focus on Neurodegenerative Disorders. Frontiers in Neuroscience, 10, 406. [Google Scholar] [CrossRef] [PubMed]
[14] Fernández-Ruiz, J., Moro, M.A., Martínez-Orgado, J., et al. (2015) Cannabinoids in Neurodegenerative Disorders and Stroke/Brain Trauma: From Preclinical Models to Clinical Applications. Neurotherapeutics, 12, 793-806. [Google Scholar] [CrossRef] [PubMed]
[15] Haug, N.A., Kieschnick, D., Sottile, J.E., et al. (2016) Training and Practices of Cannabis Dispensary Staff. Cannabis and Cannabinoid Research, 1, 244-251. [Google Scholar] [CrossRef] [PubMed]
[16] Pryce, G. and Baker, D. (2015) Endocannabinoids in Multiple Sclerosis and Amyotrophic Lateral Sclerosis. Handbook of Experimental Pharmacology, 231, 213-231. [Google Scholar] [CrossRef] [PubMed]
[17] Espejo-Porras, F., Fernández-Ruiz, J. and de Lago, E. (2018) Analysis of Endocannabinoid Receptors and Enzymes in the Post-Mortem Motor Cortex and Spinal Cord of Amyotrophic Lateral Sclerosis Patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration, 15, 1-10. [Google Scholar] [CrossRef] [PubMed]